Iván R. González: Advances in the treatment of advanced ALK+ lung cancer
Iván R. González, Medical Oncologist at Centro Oncológico Integral, Hospital Ángeles Puebla, shared a post on X:
“Advances in the treatment of advanced ALK+ lung cancer
(CROWNtrial):
Lorlatinib, a third-generation TKI, demonstrates a median progression-free survival of over 5 years in advanced ALK+ NSCLC, according to the CROWN trial.
With several second- and third-generation TKIs available, treatment selection should be based on the patient’s molecular profile.
Identification of high-risk profiles: The EML4-ALK V3 variant and TP53 mutations indicate a higher risk; monitoring with ctDNA can guide more personalized treatments.
New immunological strategies: Anti-ALK vaccines, such as those being evaluated in a new clinical trial (NCT05950139), show promise for advancing therapy.
Despite these advances, advanced ALK+ lung cancer remains a significant challenge that requires ongoing efforts to improve outcomes.”
Author: Christine M. Lovly
Source: Iván R. González/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023